Theranexus shares climbed in sustained volumes on Thursday morning on the Paris Bourse, where the biotech company posted one of the market's biggest gains after reporting positive results in Batten disease.

At around 9:30 am, the share gained over 10% in high volumes, already representing four times their daily average for the last four full trading sessions. At the same time, the CAC Mid & Small index is up 0.6%.

Theranexus this morning confirmed positive 18-month results for its drug candidate Batten-1 obtained in a Phase 1/2 trial conducted on neurofilaments, a biomarker of neuronal death.

The trial findings show a decrease in serum neurofilament light chains (NfL), with an average reduction of 33% after 18 months of treatment.

As a reminder, this rate reached 32% after 12 months of treatment.

From the biopharmaceutical company's point of view, these data confirm the therapeutic potential of Batten-1 drug candidate in the juvenile form of Batten disease.

We are continuing to evaluate all options to ensure that we have the necessary resources to set up our pivotal phase 3 trial, in Europe and the United States", emphasizes Mathieu Charvériat, the company's CEO.

In addition, Theranexus and its partner, the BBDF foundation, have set up a compassionate access program to enable the six patients who participated in the study to continue receiving the treatment, given its favorable benefit-risk ratio.

Juvenile Batten disease - also known as Spielmeyer-Vogt disease or CLN3 disease - is a rare and fatal genetic disease of the nervous system for which there is no treatment.

It generally appears between the ages of four and six, via progressive vision loss, followed by cognitive and behavioral disorders and motor difficulties.

Copyright (c) 2024 CercleFinance.com. All rights reserved.